JP2009513604A - 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 - Google Patents
月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 Download PDFInfo
- Publication number
- JP2009513604A JP2009513604A JP2008537094A JP2008537094A JP2009513604A JP 2009513604 A JP2009513604 A JP 2009513604A JP 2008537094 A JP2008537094 A JP 2008537094A JP 2008537094 A JP2008537094 A JP 2008537094A JP 2009513604 A JP2009513604 A JP 2009513604A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- acid
- formula
- use according
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 15
- 208000012201 sexual and gender identity disease Diseases 0.000 title abstract description 8
- 208000015891 sexual disease Diseases 0.000 title abstract description 8
- 150000008641 benzimidazolones Chemical class 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 97
- 239000002253 acid Substances 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 24
- 230000001568 sexual effect Effects 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 10
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 10
- 208000027520 Somatoform disease Diseases 0.000 claims description 9
- 208000027753 pain disease Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 208000024335 physical disease Diseases 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000021663 Female sexual arousal disease Diseases 0.000 claims description 3
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims description 3
- 210000004392 genitalia Anatomy 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 206010046947 vaginismus Diseases 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 208000014840 female orgasmic disease Diseases 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 201000004197 inhibited female orgasm Diseases 0.000 claims description 2
- 229940045996 isethionic acid Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 2
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
- 239000003826 tablet Substances 0.000 description 19
- 238000007792 addition Methods 0.000 description 18
- 229920002261 Corn starch Polymers 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 239000008120 corn starch Substances 0.000 description 12
- 229940099112 cornstarch Drugs 0.000 description 12
- 235000019359 magnesium stearate Nutrition 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000007941 film coated tablet Substances 0.000 description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- -1 ampoules Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 208000024309 orgasm disease Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000001107 psychogenic effect Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- DTPLOCBWAFWYND-UHFFFAOYSA-N Cl.C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 Chemical compound Cl.C=1C=CC=CC=1C(=O)C(=O)C1=CC=CC=C1 DTPLOCBWAFWYND-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101150015707 HTR1A gene Proteins 0.000 description 1
- IBAUHITZWLZMKF-UHFFFAOYSA-N Oc(cc1)c(C(F)(F)F)cc1N1CCN(CCN(c(cccc2)c2N2)C2=O)CC1 Chemical compound Oc(cc1)c(C(F)(F)F)cc1N1CCN(CCN(c(cccc2)c2N2)C2=O)CC1 IBAUHITZWLZMKF-UHFFFAOYSA-N 0.000 description 1
- SPVGJCMHEPZYNC-UHFFFAOYSA-N Oc(cc1N2)ccc1N(CCN(CC1)CCN1c1cc(C(F)(F)F)ccc1)C2=O Chemical compound Oc(cc1N2)ccc1N(CCN(CC1)CCN1c1cc(C(F)(F)F)ccc1)C2=O SPVGJCMHEPZYNC-UHFFFAOYSA-N 0.000 description 1
- BTORTJHSHQSYNZ-UHFFFAOYSA-N Oc(cc1N2CCN(CC3)CCN3c3cc(C(F)(F)F)ccc3)ccc1NC2=O Chemical compound Oc(cc1N2CCN(CC3)CCN3c3cc(C(F)(F)F)ccc3)ccc1NC2=O BTORTJHSHQSYNZ-UHFFFAOYSA-N 0.000 description 1
- PHXNVTGKJXFYGM-UHFFFAOYSA-N Oc(cccc1N2)c1N(CCN(CC1)CCN1c1cc(C(F)(F)F)ccc1)C2=O Chemical compound Oc(cccc1N2)c1N(CCN(CC1)CCN1c1cc(C(F)(F)F)ccc1)C2=O PHXNVTGKJXFYGM-UHFFFAOYSA-N 0.000 description 1
- YLVBKSCNROEACE-UHFFFAOYSA-N Oc1cccc(N2CCN(CC3)CCN3c3cc(C(F)(F)F)ccc3)c1NC2=O Chemical compound Oc1cccc(N2CCN(CC3)CCN3c3cc(C(F)(F)F)ccc3)c1NC2=O YLVBKSCNROEACE-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 208000030047 Sexual desire disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05023717 | 2005-10-29 | ||
| PCT/EP2006/067757 WO2007048803A1 (en) | 2005-10-29 | 2006-10-25 | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009513604A true JP2009513604A (ja) | 2009-04-02 |
| JP2009513604A5 JP2009513604A5 (enExample) | 2009-12-10 |
Family
ID=37638031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008537094A Pending JP2009513604A (ja) | 2005-10-29 | 2006-10-25 | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7923449B2 (enExample) |
| EP (1) | EP1945214A1 (enExample) |
| JP (1) | JP2009513604A (enExample) |
| CA (1) | CA2626134C (enExample) |
| WO (1) | WO2007048803A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| EP1912650B8 (en) | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| PT2021006E (pt) * | 2006-05-09 | 2015-11-12 | Sprout Pharmaceuticals Inc | Uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| US20090318469A1 (en) * | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| KR20090042967A (ko) | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
| CN104721168A (zh) * | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
| WO2008074795A1 (en) * | 2006-12-20 | 2008-06-26 | Boehringer Ingelheim International Gmbh | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
| WO2008090742A1 (ja) * | 2007-01-23 | 2008-07-31 | National University Corporation Hokkaido University | 眼疾患モデル用非ヒト動物 |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06509575A (ja) * | 1991-07-30 | 1994-10-27 | ベーリンガー インゲルハイム イタリア ソシエタ ペル アチオニ | ５−ＨＴ↓１↓ａ拮抗物質及び５−ＨＴ↓２ 拮抗物質としてのベンゾイミダゾロン誘導体 |
| JP2003509496A (ja) * | 1999-09-22 | 2003-03-11 | ベーリンガー インゲルハイム イタリア ソシエタ ペル アチオニ | 混合したセロトニン及びドーパミン受容体親和性を有する新規ベンズイミダゾロン誘導体 |
| WO2005007166A1 (en) * | 2003-07-16 | 2005-01-27 | Pfizer Limited | Treatment of sexual dysfunction |
| JP2007533687A (ja) * | 2004-04-22 | 2007-11-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 月経前の及び他の女性の性的障害の治療におけるフリバンセリンの使用 |
| JP2008508214A (ja) * | 2004-07-30 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 女性の性障害の治療用ピペラジン誘導体 |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3096248A (en) * | 1959-04-06 | 1963-07-02 | Rexall Drug & Chemical Company | Method of making an encapsulated tablet |
| US3406178A (en) * | 1964-02-04 | 1968-10-15 | Monsanto Chem Australia Ltd | Preparation of 2-substituted benzimidazoles |
| US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
| US4200641A (en) * | 1976-12-21 | 1980-04-29 | Janssen Pharmaceutica, N.V. | 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives |
| IL57569A0 (en) | 1978-06-20 | 1979-10-31 | Synthelabo | Phenylpiperazine derivative,their preparation and pharmaceutical compositions containing them |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| IT1176613B (it) * | 1984-08-14 | 1987-08-18 | Ravizza Spa | Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607294D0 (en) * | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| NL8601494A (nl) | 1985-06-22 | 1987-01-16 | Sandoz Ag | Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten. |
| DE3620643A1 (de) | 1985-06-22 | 1987-01-22 | Sandoz Ag | Thiazole, ihre herstellung und verwendung |
| GB8601160D0 (en) * | 1986-01-17 | 1986-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compounds |
| US5036088A (en) * | 1986-06-09 | 1991-07-30 | Pfizer Inc. | Antiallergy and antiinflammatory agents, compositions and use |
| JPH0784462B2 (ja) * | 1986-07-25 | 1995-09-13 | 日清製粉株式会社 | ベンゾイミダゾ−ル誘導体 |
| US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
| US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| GB8830312D0 (en) | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| US4954503A (en) * | 1989-09-11 | 1990-09-04 | Hoechst-Roussel Pharmaceuticals, Inc. | 3-(1-substituted-4-piperazinyl)-1H-indazoles |
| AU8629691A (en) | 1990-08-09 | 1992-03-02 | Massachusetts Institute Of Technology | Method for treating the premenstrual or late luteal phase syndrome |
| DE69129839T2 (de) | 1990-08-24 | 1999-02-11 | Shin-Etsu Chemical Co., Ltd., Tokio/Tokyo | Beschichtungsbase für einen pharmazeutischen film und verfahren zur herstellung derselben |
| NZ241613A (en) * | 1991-02-27 | 1993-06-25 | Janssen Pharmaceutica Nv | Highlighting intagliations in tablets |
| SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
| FR2675800A1 (fr) | 1991-04-26 | 1992-10-30 | Rhone Poulenc Rorer Sa | Derives heterocycliques antiserotonines leur preparation et les medicaments les contenant. |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5225417A (en) * | 1992-01-21 | 1993-07-06 | G. D. Searle & Co. | Opioid agonist compounds |
| US5492907A (en) | 1992-12-09 | 1996-02-20 | The United States Of America As Represented By The Department Of Health & Human Services | Antipsychotic composition and method of treatment |
| FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| ES2163506T3 (es) | 1994-06-14 | 2002-02-01 | Pfizer | Derivados de bencimidazolona con actividad dopaminergica central. |
| PT777477E (pt) | 1994-08-23 | 2003-03-31 | Smithkline Beecham Plc | Formulacoes farmaceuticas melhoradas contendo ibuprofen e codeina |
| ES2204932T3 (es) | 1994-09-12 | 2004-05-01 | Eli Lilly And Company Limited | Moduladores serotonergicos. |
| FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5883094A (en) * | 1995-04-24 | 1999-03-16 | Pfizer Inc. | Benzimidazolone derivatives with central dopaminergic activity |
| US5854290A (en) * | 1995-09-21 | 1998-12-29 | Amy F. T. Arnsten | Use of guanfacine in the treatment of behavioral disorders |
| US6083947A (en) * | 1996-01-29 | 2000-07-04 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
| GB9613423D0 (en) | 1996-06-26 | 1996-08-28 | Lilly Industries Ltd | Pharmaceutical compounds |
| US5916916A (en) | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| ATE271379T1 (de) | 1996-11-06 | 2004-08-15 | Wockhardt Europ Ltd | System zur verzögerten freisetzung säurelabiler substanzen |
| JP2001504851A (ja) | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 性的機能不全の治療のためのｎｋ−１受容体拮抗薬の使用 |
| US5859246A (en) | 1997-01-30 | 1999-01-12 | Neurogen Corporation | 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands |
| US20040023948A1 (en) * | 1997-03-24 | 2004-02-05 | Green Richard David | Fast-dispersing dosage form containing 5-HT1 agonists |
| GB9706089D0 (en) | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| BR9810027A (pt) * | 1997-06-11 | 2000-09-12 | Procter & Gamble | Comprimido revestido por pelìcula para melhorada segurança do trato gastrintestinal superior |
| ATE241341T1 (de) | 1997-09-10 | 2003-06-15 | Takeda Chemical Industries Ltd | Stabilisierte pharmazeutische zusammensetzung |
| SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
| CH692199A8 (fr) | 1997-10-09 | 2002-06-14 | Cermol S.A. | Composes pyridiques et compositions pharmaceutique |
| JP3724157B2 (ja) | 1997-10-30 | 2005-12-07 | コニカミノルタホールディングス株式会社 | 映像観察装置 |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| WO1999059584A1 (en) | 1998-05-20 | 1999-11-25 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
| AU3891299A (en) | 1998-05-21 | 1999-12-06 | Eli Lilly And Company | Combination therapy for treatment of depression |
| US20020151543A1 (en) | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
| US6068846A (en) | 1998-08-05 | 2000-05-30 | Melaleuca, Incorporated | Methods and materials for treating depression and mood disorder |
| EP0982030A3 (en) * | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| WO2000028993A1 (en) | 1998-11-19 | 2000-05-25 | Nortran Pharmaceuticals, Inc. | Serotonin ligands as pro-erectile compounds |
| US6680071B1 (en) * | 1999-03-03 | 2004-01-20 | R. P. Scherer Technologies, Inc. | Opioid agonist in a fast dispersing dosage form |
| WO2000063189A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
| CN1461216A (zh) | 1999-04-28 | 2003-12-10 | 呼吸器有限公司 | 用作治疗有关支气管收缩的机能障碍的药物的化合物 |
| IT1312310B1 (it) | 1999-05-07 | 2002-04-15 | Recordati Ind Chimica E Farma | Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale |
| US6579968B1 (en) | 1999-06-29 | 2003-06-17 | Palatin Technologies, Inc. | Compositions and methods for treatment of sexual dysfunction |
| US6346548B1 (en) | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| CN1396829A (zh) | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
| AU2001260548A1 (en) | 2000-06-28 | 2002-01-08 | Pfizer Products Inc. | Melanocortin receptor ligands |
| MXPA03002329A (es) | 2000-09-19 | 2003-10-15 | Boehringer Ingelheim Pharma | Nuevos derivados de bencimidazolona que muestran afinidad por los receptores de serotonina y dopamina. |
| US6521623B1 (en) * | 2000-09-19 | 2003-02-18 | Boehringer Ingelheim Pharma Kg | N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| US6586435B2 (en) * | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| AU2002226895B2 (en) | 2000-11-22 | 2006-10-12 | Abbott Laboratories | Selective dopamine D4 receptor agonists for treating sexual dysfunction |
| GB0105893D0 (en) | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
| KR100564466B1 (ko) | 2001-03-28 | 2006-03-29 | 화이자 인코포레이티드 | Ｆｓａｄ에 대한 ｎｅｐ 억제제로서의ｎ-펜프로필사이클로펜틸-치환된 글루타르아미드 유도체 |
| DE60121301T2 (de) * | 2001-05-11 | 2007-07-19 | Beck, Jürgen, Dr. | Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| US7115628B2 (en) | 2001-07-18 | 2006-10-03 | Merck & Co., Inc. | Bridged piperidine derivatives as melanocortin receptor agonists |
| DE60231070D1 (de) | 2001-07-30 | 2009-03-19 | Spectrum Pharmaceuticals Inc | Arylpiperazin gebundene Purinderivate |
| AU2002331361B2 (en) | 2001-08-02 | 2008-06-05 | Sprout Pharmaceuticals, Inc. | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
| US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| DE10138273A1 (de) | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
| US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
| HUP0202719A3 (en) | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| DE10209982A1 (de) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
| RS51718B (sr) | 2002-05-22 | 2011-10-31 | Boehringer Ingelheim Pharma Gmbh. & Co.Kg. | Nove farmaceutske kompozicije koje sadrže flibanserin polimorf a |
| US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| US20040132697A1 (en) | 2002-11-06 | 2004-07-08 | Pfizer Inc. | Treatment of female sexual dysfunction |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| WO2004063864A2 (en) * | 2003-01-06 | 2004-07-29 | Laura Berman | Method and system for computerized sexual function assessment of female users |
| WO2004069339A1 (en) | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
| US20050037983A1 (en) | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| WO2005044238A1 (en) | 2003-11-07 | 2005-05-19 | Ranbaxy Laboratories Limited | Modified release solid dosage form of amphetamine salts |
| EP1740181A1 (en) * | 2004-04-22 | 2007-01-10 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
| US20060014757A1 (en) * | 2004-07-14 | 2006-01-19 | Boehringer Ingelheim Pharmaceuticals | Method for the treatment of anorexia nervosa |
| EP1789048A1 (en) | 2004-09-03 | 2007-05-30 | Boehringer Ingelheim International GmbH | Method for the treatment of attention deficit hyperactivity disorder |
| JP2008531714A (ja) * | 2005-03-04 | 2008-08-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 不安障害の治療用及び／又は予防用の医薬組成物 |
| CA2599721A1 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| CA2608249A1 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug abuse with flibanserin |
| US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
| JP2008540673A (ja) * | 2005-05-19 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 薬剤誘発性性機能不全の治療方法 |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| EP1912650B8 (en) | 2005-08-03 | 2017-10-18 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
| HU227490B1 (en) | 2005-08-26 | 2011-07-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Sustained release pharmaceutical preparation containing carvedilol |
| EP1945214A1 (en) | 2005-10-29 | 2008-07-23 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| KR20140088230A (ko) | 2006-01-27 | 2014-07-09 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
| CA2641917A1 (en) | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
| EP1988897A1 (en) | 2006-02-20 | 2008-11-12 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of urinary incontinence |
| CA2642368A1 (en) | 2006-02-28 | 2007-09-07 | Boehringer Ingelheim International Gmbh | Treatment of prevention of valvular heart disease with flibanserin |
| PT2021006E (pt) | 2006-05-09 | 2015-11-12 | Sprout Pharmaceuticals Inc | Uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa |
| JP2009541443A (ja) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 尿失禁及び関連疾患の治療のためのフリバンセリン |
| US20090318469A1 (en) | 2006-07-14 | 2009-12-24 | Boehringer Ingelheim International Gmbh | Use of Flibanserin for the Treatment of Sexual Disorders in Females |
| WO2008006839A2 (en) | 2006-07-14 | 2008-01-17 | Boehringer Ingelheim International Gmbh | Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments |
| KR20090042967A (ko) * | 2006-08-14 | 2009-05-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 플리반세린 제형 및 이의 제조방법 |
| CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| CN104721168A (zh) | 2006-08-25 | 2015-06-24 | 贝林格尔·英格海姆国际有限公司 | 控制释放系统及其制造方法 |
-
2006
- 2006-10-25 EP EP06807537A patent/EP1945214A1/en not_active Withdrawn
- 2006-10-25 CA CA2626134A patent/CA2626134C/en not_active Expired - Fee Related
- 2006-10-25 US US12/091,848 patent/US7923449B2/en not_active Expired - Fee Related
- 2006-10-25 JP JP2008537094A patent/JP2009513604A/ja active Pending
- 2006-10-25 WO PCT/EP2006/067757 patent/WO2007048803A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06509575A (ja) * | 1991-07-30 | 1994-10-27 | ベーリンガー インゲルハイム イタリア ソシエタ ペル アチオニ | ５−ＨＴ↓１↓ａ拮抗物質及び５−ＨＴ↓２ 拮抗物質としてのベンゾイミダゾロン誘導体 |
| JP2003509496A (ja) * | 1999-09-22 | 2003-03-11 | ベーリンガー インゲルハイム イタリア ソシエタ ペル アチオニ | 混合したセロトニン及びドーパミン受容体親和性を有する新規ベンズイミダゾロン誘導体 |
| WO2005007166A1 (en) * | 2003-07-16 | 2005-01-27 | Pfizer Limited | Treatment of sexual dysfunction |
| JP2007533687A (ja) * | 2004-04-22 | 2007-11-22 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 月経前の及び他の女性の性的障害の治療におけるフリバンセリンの使用 |
| JP2008508214A (ja) * | 2004-07-30 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 女性の性障害の治療用ピペラジン誘導体 |
Non-Patent Citations (3)
| Title |
|---|
| JPN5008016787; ＳＩＥＴＳＥＭＡ: ＧＯＯＤ ＣＬＩＮＩＣＡＬ ＰＲＡＣＴＩＣＥ ＪＯＵＲＮＡＬ Ｖ１２ Ｎ１, 200501, Ｐ２３-２７, ＢＲＯＯＫＷＯＯＤ ＭＥＤＩＣＡＬ ＰＵＢＬＩＣＡＴＩＯＮＳ * |
| JPN5008016790; ＷＡＬＳＨ Ｋ Ｅ: ＤＲＵＧＳ ＡＮＤ ＡＧＩＮＧ Ｖ２１ Ｎ１０, 2004, Ｐ６５５-６７５, ＡＤＩＳ ＩＮＴＥＲＮＡＴＩＯＮＡＬ ＬＴＤ * |
| JPN5008016792; ＭＯＹＮＩＨＡＮ，Ｒ．: ＢＲＩＴＩＳＨ ＭＥＤＩＣＡＬ ＪＯＵＲＮＡＬ Ｖ３２６, 20030104, Ｐ４５-４７ * |
Also Published As
| Publication number | Publication date |
|---|---|
| US7923449B2 (en) | 2011-04-12 |
| CA2626134A1 (en) | 2007-05-03 |
| CA2626134C (en) | 2013-12-24 |
| WO2007048803A1 (en) | 2007-05-03 |
| EP1945214A1 (en) | 2008-07-23 |
| US20080242679A1 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101235102B1 (ko) | 플리반세린을 포함하는 성욕 장애 치료용 약제학적 조성물 | |
| JP2009536176A (ja) | 閉経後の性的欲求障害の治療のためのフリバンセリンの使用 | |
| JP2009513604A (ja) | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 | |
| JP5386173B2 (ja) | 閉経前の性的欲求障害の治療のためのフリバンセリンの使用 | |
| JP2009513602A (ja) | ベンズイミダゾロン誘導体を含んだ性欲増強薬 | |
| AU2002333894A1 (en) | Use of flibanserin in the treatment of sexual disorders | |
| WO2005102343A1 (en) | Use of flibanserin in the treatment of premenstrual and other female sexual disorders | |
| WO2008061968A1 (en) | Benzimidazolone derivates in the treatment of pulmonary arterial hypertension | |
| JP2010518040A (ja) | 不眠症を治療するためのフリバンセリンの使用 | |
| CN101443011A (zh) | 氟班色林于治疗绝经后性欲障碍的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091022 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091022 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120507 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121015 |